Phase I dose escalation study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) & Follicular Lymphoma (FL): The RaDD study

Primary Sponsor

ONJRI

Collaborating Groups

TROG Cancer Research

Participating Centres

Current Accrual

Trial Chairperson

Dr Eliza Hawkes, Olivia Newton John Cancer Research Institute, Austin Health

Trial Contact

qa@trog.com.au

Related Post

August 2, 2022

Celebrating and bringing radiation medicine research to the forefront at our 2022 ASM

After a hiatus from in-person events due to COVID-19

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a